Disease · EFO_0009963

bipolar I disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. bipolar I disorder. Diseases, record EFO_0009963. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009963

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: bipolar I disorder; Open Targets
Open Targets ID: EFO_0009963; Open Targets
Disease Ontology: DOID:14042; Disease Ontology
Highest stage of its drugs: Approval, for 15 of its 41 drugs, from DailyMed and FDA; Open Targets

Drugs41

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OLANZAPINE	CHEMBL715	Small molecule	Approval	DailyMed	20	14	14	Drugs and targets
ARIPIPRAZOLE	CHEMBL1112	Small molecule	Approval	DailyMed	17	12	12	Drugs and targets
LITHIUM CARBONATE	CHEMBL1200826	Small molecule	Approval	DailyMed	11	7	3	Drugs and targets
RISPERIDONE	CHEMBL85	Small molecule	Approval	DailyMed	10	5	5	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Approval	DailyMed	8	5	5	Drugs and targets
QUETIAPINE FUMARATE	CHEMBL3188993	Small molecule	Approval	DailyMed	8	5	5	Drugs and targets
CARBAMAZEPINE	CHEMBL108	Small molecule	Approval	DailyMed	6	5	5	Drugs and targets
ASENAPINE MALEATE	CHEMBL3544974	Small molecule	Approval	DailyMed	5	3	3	Drugs and targets
ASENAPINE	CHEMBL3187365	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
FLUOXETINE HYDROCHLORIDE	CHEMBL1201082	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets

1 to 10 of 41

See all 41 drugs

Targets66

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DRD2	D(2) dopamine receptor	19	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator; Dopamine D2 receptor partial agonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	17	Serotonin 2a (5-HT2a) receptor antagonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	7	Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
DRD3	D(3) dopamine receptor	5	D2-like dopamine receptor antagonist; D2-like dopamine receptor inverse agonist; Dopamine D3 receptor modulator	Approval	https://conductscience.org/library/genes/1814	Drugs and targets
SCN10A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	4	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets

1 to 10 of 66

See all 66 targets

Trials89

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00277212	A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode	Phase 4	1,169	2010-10-20	Bipolar Disorder	ARIPIPRAZOLE, LAMOTRIGINE	Its record names the disease	ClinicalTrials.gov
NCT01710709	Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder	Phase 3	748	2018-08-08	Bipolar I	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01467713	Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder	Phase 3	642	2016-05-16	Bipolar Disorder	RAMELTEON	Its record names the disease	ClinicalTrials.gov
NCT00280566	Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)	Phase 3	584	2009-12-14	Bipolar Mania, Bipolar Disorder	LITHIUM, VALPROIC ACID, ZIPRASIDONE	Its record names the disease	ClinicalTrials.gov
NCT01122927	Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.	Phase 3	524	2016-02-08	Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03201757	Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831	Phase 3	523	2024-09-26	Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder	OLANZAPINE, SAMIDORPHAN	Its record names the disease	ClinicalTrials.gov
NCT01058668	Safety and Efficacy of Cariprazine for Bipolar I Disorder	Phase 3	497	2017-04-12	Mania, Bipolar I Disorder	CARIPRAZINE	Its record names the disease	ClinicalTrials.gov
NCT01986114	A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.	Phase 3	495	2019-07-23	Bipolar I Disorder	LURASIDONE	Its record names the disease	ClinicalTrials.gov
NCT00665366	Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder	Phase 3	493	2013-02-04	Bipolar Disorder Mania	ARIPIPRAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01467700	Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder	Phase 3	490	2016-05-16	Acute Depressive Episode	RAMELTEON	Its record names the disease	ClinicalTrials.gov

1 to 10 of 89

See all 89 trials

Comparisons in its trials54

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Conversion Phase vs Open-label Treatment Phase: serious adverse events	2 of 297	49 of 510	807	NCT01122927	Trial comparisons
SM-13496 20-120mg (Overall, 28 Weeks) vs SM-13496 20-120mg (Japan, 52 Weeks): Number of Subjects Who Experienced Recurrence/Relapse of Any Mood Event From Clinical Stability of Bipolar Disorder.	14 of 495	18 of 199	694	NCT01986114	Trial comparisons
SM-13496 20-120mg (Overall, 28 Weeks) vs SM-13496 20-120mg (Japan, 52 Weeks): Number of Subjects With at Least One Adverse Event (AE) and Adverse Drug Reaction (ADR)	352 of 495	169 of 199	694	NCT01986114	Trial comparisons
SM-13496 20-120mg (Overall, 28 Weeks) vs SM-13496 20-120mg (Japan, 52 Weeks): deaths from any cause	0 of 495	0 of 199	694	NCT01986114	Trial comparisons
SM-13496 20-120mg (Overall, 28 Weeks) vs SM-13496 20-120mg (Japan, 52 Weeks): serious adverse events	19 of 495	12 of 199	694	NCT01986114	Trial comparisons
ALKS 3831 vs Olanzapine: Number of Participants Experiencing of Adverse Events (AEs)	134 of 211	136 of 215	426	NCT03187769	Trial comparisons
ALKS 3831 vs Olanzapine: deaths from any cause	1 of 211	0 of 215	426	NCT03187769	Trial comparisons
ALKS 3831 vs Olanzapine: serious adverse events	8 of 211	8 of 215	426	NCT03187769	Trial comparisons
Armodafinil 150 mg/Day vs Placebo: serious adverse events	5 of 200	6 of 198	398	NCT01305408	Trial comparisons
Aripiprazole vs Placebo: serious adverse events	11 of 180	17 of 189	369	NCT00665366	Trial comparisons

1 to 10 of 54

See all 54 comparisons in its trials

Papers from its trials57

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35503059	RESULT	1	PubMed
26598478	RESULT	2	PubMed
25099397	RESULT	1	PubMed
22213771	RESULT	1	PubMed
22198448	RESULT	1	PubMed
20861739	RESULT	1	PubMed
17854242	RESULT	1	PubMed
15169694	RESULT	1	PubMed
41944742	DERIVED	1	PubMed
41778148	DERIVED	1	PubMed

1 to 10 of 57

See all 57 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0009963

GET https://conductscience.org/api/diseases/v1/EFO_0009963/drugs?page=2

API reference For AI assistants